GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, ...

GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational ...

GSK announced in January that its novel chronic hepatitis B (CHB) successfully met primary goals in two pivotal phase 3 ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

Hepatitis B is a virus that can damage the liver and lead to lifelong health problems. The hepatitis B vaccine prevents short ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

Earlier this week, GSK and Ionis Pharmaceuticals reported that their antisense drug bepirovirsen achieved primary endpoints in two Phase 3 trials for chronic hepatitis B, showing a statistically ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.

There has been a lot of public attention surrounding pediatric hepatitis B vaccines recently. Are they safe? Are they ...